News & Stories
Check out our latest stories
Positive results from ProDERM study of octagam® 10% in patients with dermatomyositis meeting the primary endpoint will be presented at ACR Convergence 2020
Octapharma announces FDA approval of updated NUWIQ
Prescribing Information will include immunogenicity data in previously untreated patients.